Kathy. Jaworski, et.al., AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency., Nature medicine, 2009, 15

http://rdf.ncbi.nlm.nih.gov/pubmed/19136964

Kathy. Jaworski, et.al., AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency., Nature medicine, 2009, 15

http://rdf.ncbi.nlm.nih.gov/pubmed/

トランスクリプトームデータ

http://rdf.ncbi.nlm.nih.gov/pubmed/

• CD11552
  http://metadb.riken.jp/db/BrainTx/TranscriptomeData/CD11552

allele

http://purl.org/net/cito/citesAsAuthority

• Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/db/mgi_rdf/MGI:5882500

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• impaired cellular glucose import_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0003926B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• enlarged liver_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0000599B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased liver triglyceride level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0009356B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased phospholipase A2 level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0012634B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased renal fat pad weight_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0009303B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased circulating triglyceride level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002644B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased circulating free fatty acid level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002702B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• enhanced lipolysis_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0008034B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased circulating insulin level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002079B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased circulating glucose level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005559B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased triglyceride level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005318B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• abnormal glycogen homeostasis_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005438B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased susceptibility to diet-induced obesity_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005659B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased oxygen consumption_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005289B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased white fat cell size_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0009133B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• hepatic steatosis_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002628B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased fasted circulating glucose level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0013279B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased fatty acid oxidation_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0014171B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased susceptibility to weight gain_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0010182B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased epididymal fat pad weight_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0009289B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased circulating leptin level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005668B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased circulating alanine transaminase level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002941B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• abnormal glucose homeostasis_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0002078B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• pale liver_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0000603B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• increased lean body mass_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0003960B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• abnormal lipid metabolism_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0013245B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• insulin resistance_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0005331B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased inguinal fat pad weight_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0009293B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul
• decreased adiponectin level_Pla2g16<tm1.1Hsul>/Pla2g16<tm1.1Hsul>
  http://metadb.riken.jp/0004893B6129P2Pla2g16tm11HsulPla2g16tm11HsulPla2g16tm11HsulPla2g16tm11Hsul